MIRA PHARMACEUTICALS, INC. (MIRA) Stock Profile — Insider Trades & Financials

EPS$-1.45

Market Cap$43.9M

Price Performance

Historical data including institutional events

Loading price data...

Company Profile

Erez Aminov

CEO & Executive Director

MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder. In addition, its oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is based in Miami, Florida.

Founded: 2020
Employees: 3

⚡

Core Efficiency

D/E Ratio?

0.07

📊

Profitability Ratios

Current Ratio?

15.75

Loading comparison...

Earnings Calendar

Filing history and next expected filing date

Next Expected Filing

Aug 29, 2026 (in 142 days)

Annual Report (10-K) — Based on filing pattern

Aug 29, 2026

Predicted10-K

Mar 31, 2026

10-KQ4 20251d after period end

Nov 13, 2025

10-QQ3 20252d after period end

Aug 14, 2025

10-QQ2 20251d after period end

May 14, 2025

10-QQ1 20250d after period end

Apr 17, 2025

10-K/AQ4 202420d after period end

May 13, 2024

10-QQ1 2024-184d after period end

Nov 12, 2024

10-QQ3 20240d after period end

Aug 16, 2024

10-Q/AQ2 20243d after period end

Loading company sections...

MIRA PHARMACEUTICALS, INC.

Price Performance

Company Profile

Core Efficiency

Profitability Ratios

Earnings Calendar

Core Efficiency

Profitability Ratios

Earnings Calendar

Data Freshness